Robert Nelsen - Jan 5, 2023 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role
Director, 10%+ Owner
Signature
/s/ Nathan Hardy, Attorney-in-Fact for Robert Nelsen
Stock symbol
SANA
Transactions as of
Jan 5, 2023
Transactions value $
$0
Form type
4
Date filed
1/6/2023, 03:19 PM
Previous filing
Oct 26, 2022
Next filing
May 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SANA Common Stock Award $0 +536 +65.61% $0.00 1.35K Jan 5, 2023 Direct F1
holding SANA Common Stock 12.5K Jan 5, 2023 See footnote F2
holding SANA Common Stock 10.3M Jan 5, 2023 See footnotes F3, F4, F5
holding SANA Common Stock 10.3M Jan 5, 2023 See footnotes F4, F5, F6
holding SANA Common Stock 11.7M Jan 5, 2023 See footnotes F5, F7, F8
holding SANA Common Stock 11.7M Jan 5, 2023 See footnotes F5, F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of fully vested restricted stock units.
F2 The shares were received by Enzo Family Trust of 2015 in a distribution of shares upon the dissolution of Sana Investors, LLC. The Reporting Person's minor children are the beneficiaries of Enzo Family Trust of 2015.
F3 Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
F4 ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP). Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to the extent of any pecuniary interest therein.
F5 The Reporting Person is an AVP IX MD and a member, along with Keith Crandell, Kristina Burrow and Steven Gillis, of the investment committee (the AVP X Committee Members) of ARCH Venture Partners X, LLC (AVP X LLC), and may be deemed to beneficially own the shares held by ARCH IX, ARCH IX Overage, ARCH Venture Fund X, L.P. (ARCH X), and ARCH Venture Fund X Overage, L.P. (ARCH X Overage). The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.
F6 Represents shares held directly by ARCH IX Overage. AVP IX Overage LP is the sole general partner of ARCH IX Overage.
F7 Represents shares held directly by ARCH X. ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
F8 AVP X LLC is the sole general partner of each of AVP X LP and ARCH Venture Partners X Overage, L.P. (AVP X Overage LP). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.
F9 Represents shares held directly by ARCH X Overage. AVP X Overage LP is the sole general partner of ARCH X Overage.